Wednesday, March 29, 2023


Biotechnology News Magazine

Germo Gericke MD Appointed Chief Medical Officer of Ariceum Therapeutics

Latest Posts

Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer

ACTO advises Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning culture could eliminate this behavior.

Entrinsic Bioscience® Expands enterade® Brand with Innovative Approach to the Dietary Support of Irritable Bowel Syndrome with Diarrhea (IBS-D

enterade® IBS-D is the first medical food formulated with plant-based amino acids and electrolytes for Irritable Bowel Syndrome with Diarrhea (IBS-D)-

Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve

To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.

How Biotech Businesses Can Benefit from Freelance Experts

Ashmita Das, CEO of open talent platform Kolabtree, shares some of Kolabtree freelancer’s success stories.

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Germo Gericke, M.D., as Chief Medical Officer.

Germo joins Ariceum from Novartis, where he has recently served as Chief Medical Officer and Global Head of Research and Development at Advanced Accelerator Applications (AAA), a Novartis company specializing in the field of nuclear medicine. Germo will be based at Ariceum’s newly opened subsidiary in Basel, Switzerland.  Basel offers one of the largest talent pools in Europe for the development and commercialization of innovative pharmaceuticals.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “I am delighted to welcome Germo to the Ariceum leadership team at a pivotal time of Company growth and clinical development. Germo brings with him a wealth of experience in the field of radiopharmaceutical therapy and it is a testament to the potential of Ariceum’s theranostic portfolio that someone of Germo’s calibre has chosen to join our team. Germo will build and lead the clinical development and operations team out of our new subsidiary in Basel.”

Germo Gericke, M.D., Chief Medical Officer of Ariceum Therapeutics, commented:

“I am excited to join Ariceum with its focus on systemic targeted radiotherapy. Ariceum is actively working to develop innovative medicines for the diagnosis, monitoring, and precision treatment of certain aggressive neuroendocrine cancers, such as small cell lung cancer (SCLC).  These cancers have few treatment options and poor prognoses, and so I look forward to contributing to Ariceum’s mission to improve the lives of those facing these very challenging diseases.”

Germo joins Ariceum from Advanced Accelerator Applications (AAA), a Novartis company developing targeted radioligand therapies and precision imaging radioligands for oncology indications.  As a member of the Executive Leadership Team, he held positions of Chief Medical Officer and Head of Research and Development building a global R&D organization for Radioligand Therapies. Prior to AAA, Germo served as Franchise Global Program Head in Oncology Development and in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas, having joined Novartis in 2001 from McKinsey & Company. Germo studied medicine at Charité University Hospital in Berlin and holds an MD from the University of Heidelberg.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine